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Background: The treatment of Nocardia species found in the sputum of cystic fibrosis patients is of unknown value.
Methods:We conducted a retrospective analysis of the impact of directed oral antibiotic therapy against Nocardia spp. isolated from the sputum of
17 cystic fibrosis patients over a 10-year period. Pulmonary Function Tests were used as the clinical indicator of the disease state and the data were
analyzed by general linear mixed model statistics with univariate analysis.
Results: Pulmonary Function Test values of all patients studied showed no significant difference before, during, or after the antibiotic treatment
period. Treatment groups did not differ from non-treatment groups. This held true for Forced Expiratory Volume over 1 s and Functional Vital
Capacity analysis. In addition, individual patient analysis did not reveal any trends or outliers.
Conclusions: Oral antibiotic therapy of cystic fibrosis patients colonized with Nocardia does not appear to affect clinical outcome. This suggests
that deferring therapy may be an acceptable alternative and justifies conducting a future placebo controlled trial. In addition, this study model may
be useful in analyzing the effect of therapy on other rare and difficult organisms, such as fungi and mycobacteria in the cystic fibrosis population.
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Nocardia spp. are a collection of gram variable rods that are
common soil inhabitants and widespread geographically. This
actinomycete can cause a range of human disease from localized
cutaneous eruptions, to dissemination and death. Pulmonary
nocardiosis can be a cause of disease in populations with risk
factors such as immunosuppression, malignancies, and severe
lung disease [1]. Although rare in most of the world, the deserts
of the Southwest United States appear to have a high incidence
of disease associated with certain Nocardia species [2]. Of the
cystic fibrosis patients in our clinic, roughly 14% have Nocar-
dia isolated from the sputum at some point during their clinical⁎ Corresponding author. 1501 N. Campbell Avenue, Tucson, AZ 85724,
United States. Tel.: +1 520 626 6887; fax: +1 520 626 5183.
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doi:10.1016/j.jcf.2009.07.005followup. This finding in cystic fibrosis patients has been rarely
studied [3,4]. Determining the difference between Nocardia
infection versus colonization is extremely challenging in cystic
fibrosis due to universally abnormal chest imaging, the
inconsistency of patient's clinical symptoms, and the lack of
objective data regarding host interactions with the pathogen.
For example, it is well known that patients with cystic fibrosis
can commonly harbor highly virulent and resistant organisms
such as Pseudomonas without the severe systemic illnesses that
frequently accompany them. The usual approach to these
patients has been to administer antibiotic therapy when No-
cardia is isolated, regardless of the patient's clinical state. It is
unclear, however, whether this results in an improvement in the
pulmonary status of the patients. To complicate the picture,
antibiotic therapy for Nocardia is not benign, and appropriate
duration of therapy is completely unknown. In the past, these
questions could not be addressed because of the small numberd by Elsevier B.V. All rights reserved.
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We developed a model allowing us to investigate the basic
question of antibiotic efficacy in patients with cystic fibrosis
and pulmonary Nocardia.
2. Methods
2.1. Selection of patients
The protocol was deemed exempt by the University of
Arizona Institutional Review Board due to its retrospective
nature. Potential subjects were identified utilizing a laboratory
microbiology database. Patients with cystic fibrosis and a
sputum culture positive for Nocardia spp. were selected from
the data pool for the time period of December 1997 to
December 2007. Individuals were then screened for eligibility
for the following inclusion criteria. First, the patient must have
had a sputum culture positive for Nocardia spp. Second, there
had to be adequate Pulmonary Function Test (PFT) data during
the period of interest. Exclusion criteria included any period of
prolonged antibiotic therapy (defined as greater than 2 months)
for any reason not pertaining to the treatment of Nocardia
infection. Nocardia infections typically require many months of
antibiotic treatment for cure or control, an important factor
differentiating them from many other bacterial infections.
Medical records were reviewed and the following data was
collected for analysis: positive cultures and gram stains,
concurrent hospitalizations, Nocardia species, period of anti-
biotic therapy, type of antibiotic, and PFT values for the
preceding and following 6 months coinciding with each positive
culture. Age, sex and height adjustment were recorded, and
were accounted for in the percent-predicted values for lung
function tests Forced Expiratory Volume over 1 s (FEV1) and
Functional Vital Capacity (FVC).
2.2. Study design
Each patient's positive cultures for Nocardia were divided
separately into “episodes”. An episode consisted of either a
positive culture, or a subsequent sputum gram stain morpho-
logically consistent with Nocardia spp., i.e., the presence of
beaded, branching, modified acid fast positive rods in chains.
Pulmonary function testing was used as a surrogate marker for
disease progression or improvement. This was considered the
most accurate measure of lung function retrospectively avail-
able. FEV1 and FVC percent predicted values were recorded
6 months prior to each episode and 6 months after each episode.
A mean PFT value was calculated for the 6 months prior to the
episode and the 6 months following the episode and treatment
(if applicable). All patients received PFT testing on multiple
occasions during each collection period. Mean PFTs pre-
episode and post-episode were then compared individually and
as a group. In addition, the total number of episodes was
similarly divided into treatment and a non-treatment groups.
Since the treatment vs non-treatment analysis and the pre-
treatment vs post-treatment analysis were not exclusive, a
mixed model approach was utilized to combine the data.2.3. Statistical analyses
Complex longitudinal statistical methods were utilized to
allow analysis of multiple subsequent episodes in the same
patient. Frequencies were calculated for each categorical
variable and means and standard deviations computed for
continuous variables. Because there were repeated measures for
each subject, general linear mixed models (GLMM) were used.
GLMM uses all data contributions for a subject regardless of
missing values and accounts for within-subject correlation
related to longitudinal measures [5]. Analyses were carried out
using Stata 10 (StataCorps. 2007. Statistical software: Release
10.0. College Station, TX: Stata Corporation). A random effect
for subject was fitted in the two final models. One model was
used for FEV1 as the outcome measure and one model for FVC.
Linear trends across time were assessed and potential
confounders were considered for the final models. Results
were considered significantly different if P wasb .05.
2.4. Antibiotics
Standard of care for oral treatment of Nocardia has
traditionally involved a sulfa-based antibiotic as first line
treatment, however resistance has been described [6]. Antibiotic
sensitivities were available for less than a third of the isolates.
Optimal duration of therapy is unknown and dependant on
individual presentation and response, however prolonged
therapy (months) has shown greater clinical efficacy than
shorter courses. Therefore for purposes of this study, a treatment
course was defined as 2 consecutive months or greater of an oral
antibiotic including: trimethoprim-sulfamethoxazole, minocy-
cline, or doxycycline. Several intravenous antibiotics are
effective against Nocardia, namely carbapenems, ceftriaxone,
and amikacin. The effect of intravenous antibiotics will be
discussed below.
2.5. Effect of hospitalizations
We acknowledge the possibility that intermittent hospitaliza-
tions could bias the results due to the administration of short
courses of intravenous antibiotics directed at a pathogen such as
Pseudomonas which may have incidental anti-Nocardia
qualities. Hence, hospitalizations chronologically associated
with the episodes of Nocardia-positive sputum were recorded
and controlled for statistically using the mixed model, and a
separate univariate analysis of the data.
3. Results
3.1. Demographics
A total of 123 persons with positive Nocardia cultures and
123 patients with cystic fibrosis were identified from our
institution during the 10 year period. Seventeen of these patients
(14%) had cystic fibrosis. No patient with cystic fibrosis met
exclusion criteria, hence all patients identified were included in
the analysis. There were 11 male and six female patients. The
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however at the specific time of diagnosis each patient was of
appropriate age to successfully perform PFTs (Table 1). No
patient in this study was known to have additional risk factors
other than cystic fibrosis for Nocardia infection. In addition, all
patients exhibited Nocardia in the sputum only, with no
evidence of extrapulmonary disease or dissemination.
Nocardia species. N. asteroides was identified in 13 patients,
N. farcinica in one patient, N. transvalensis in one patient, N.
cyriacigeorgica in one patient, and N. otitidiscavariaum in one
patient (Table 1). No patient exhibited more than one species of
Nocardia. Several patients were noted to have persistent No-
cardia-positive sputa by culture and gram stain despite repeated
antibiotic courses. They were included in this analysis and did
not appear to have outcomes different from the patients with a
single isolated culture. There was an average of 5.3 episodes of
documented Nocardia-positive sputum per patient.
3.2. Antibiotic usage
Trimethoprim-sulfamethoxazole was the most utilized oral
therapy, with 13 individuals exclusively receiving this anti-
biotic. Three patients received minocycline only. One patient
received trimethoprim-sulfamethoxazole, minocycline, and
doxycycline on different occasions. Of 90 total episodes, 78%
(70) were considered “treated” by study criteria. No patient in
this series received intravenous antibiotics for a duration greater
than 2 weeks. Drug susceptibility of the Nocardia isolates
remained stable over time in those patients where serial culture
and susceptibility were performed.
3.3. FEV1
Fig. 1 plots mean FEV1 values over time for each patient for
1 year's duration, 6 months prior to isolation of NocardiaTable 1
Patient information.
Patient Sex Age Nocardia spp. Number of No
1 F 18 N. cyriacigeorgica 7
2 M 34 N. asteroides 1
3 F 23 N. asteroides 13
4 M 24 N. asteroides 3
5 M 38 N. asteroides 5
6 F 17 N. transvalensis 1
7 M 12 N. asteroides 1
8 F 19 N. asteroides 20
9 M 25 N. otitidiscavariaum 3
10 M 27 N. asteroides 18
11 F 53 N. asteroides 1
12 M 19 N. asteroides 1
13 M 21 N. asteroides 6
14 M 36 N. asteroides 7
15 M 20 N. farcinica 1
16 M 17 N. asteroides 1
17 F 18 N. asteroides 1
Total 90followed by 6 months of FEV1 values during and after therapy
for Nocardia colonization. No significant linear trends were
found in the FEV1 over time. Individual subject data
demonstrates the overall lack of change in lung function over
time as well as confirming the aggregated data of the group.
Comparing the mean values in the treated and untreated groups
was not significant for FEV1 (p=0.056) (Table 2). A total of 46
pre-episode mean PFT values and 46 post-episode mean PFT
values were evaluated in this study.3.4. FVC
Fig. 2 plots FVC values in a similar fashion to Fig. 1. No
significant linear trends were found. Individual subject data also
demonstrates an overall lack of change in lung function over
time, again confirming the aggregated data of the group.
Comparing the mean values in the treated and untreated
groups was not significant for FVC (p=0.215) (Table 2). A total
of 46 pre-episode mean PFT values and 46 post-episode mean
PFT values were evaluated in this study.3.5. Effect of hospitalizations
100 hospitalizations chronologically associated with Nocar-
dia-positive sputum were encountered during the study period.
Nearly all hospitalizations involved the administration of one or
more antibiotics. Intravenous antibiotic courses were exclu-
sively clustered around hospitalizations and no patient received
a single intravenous antibiotic for a documented period greater
than 2 weeks. The most frequently encountered antibiotics
expected to be active against Nocardia were carbapenems and
ceftriaxone. In the statistical analysis, the p-value for effect of
hospitalization was 0.122 in the full model and 0.123 in the





















Fig. 1. Averages of FEV1 values for each subject 180 days before and 180 days
after antibiotic start date (start date=0) for each episode. The mean values for
each subject are a different color. Two subjects did not receive antibiotics and
were not included in this graph. The bold black line represents an aggregate of
all patient values.
Fig. 2. Averages of FVC values for each subject 180 days before and 180 days
after antibiotic start date (start date=0). The mean values for each subject are a
different color. The bold black line represents an aggregate of all patient values.
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the overall PFT analysis.
4. Discussion
Patients with cystic fibrosis have a predisposition to
colonization and infection with a large array of microbes,
many of which are not commonly seen in the general population
[6]. Some of these have been shown to accelerate the clinical
deterioration of pulmonary function in cystic fibrosis such as
Pseudomonas aeruginosa [7]. Other microorganisms reportedly
pathogenic in cystic fibrosis are Burkholderia cepacia complex,
Staphylococcus aureus, Hemophilus influenzae, Stenotropho-
monas maltophilia, Achromobacter xylosoxidans and Asper-
gillus species [8]. Many microorganisms, however, have little or
no data to define their role as a pathogen or colonizer in the
cystic fibrosis patient. These include various fungi such as
Scedosporium, non-tuberculous Mycobacteria, Actinomycetes,
Legionella, Mycoplasma, and even respiratory viruses [9]. The
reasons for the lack of data are multiple including the fact that
cystic fibrosis patients have a constantly changing array of
microorganisms as well as frequent antibiotic use (directed or
empirical), multiple organ comorbidities, and numerous
hospitalizations.
The literature describing Nocardia in cystic fibrosis includes
one report describing three patients in Australia [3] and one
report of nine patients in Spain [4]. The conclusions of these
reports suggest that isolation of Nocardia spp. from sputum
likely represents colonization rather than infection. Most
patients in both case series were treated with oral cotrimoxazole.
Patients who were not treated had similar outcomes to theTable 2
Statistical analysis of treatment outcomes using FVC and FEV1.
Coefficient Std. err. Z p-value 95% C.I.
FEV1 3.05 1.60 1.91 0.056 −0.084–6.19
FVC 1.87 1.51 1.24 0.215 −1.08–4.83
Combined significance of treatment vs. non-treatment groups, and pre-treatment
vs. post-treatment groups in a mixed model.treated patients, and PFTs were unchanged throughout. In
addition, there was no change in patient symptoms in either
report.
Our study represents an attempt to systematically quantify
the effects of treatment of a rare microorganism in cystic
fibrosis. The data from this analysis concurs with prior
anecdotal reports that treatment of Nocardia-positive sputum
in the setting of cystic fibrosis likely has little or no value in
improving pulmonary function. Figs. 1 and 2 illustrate the lack
of effect of antibiotics on FEV1 values and FVC values,
respectively. One would expect a “V” shaped line in the event
that treatment of Nocardia was beneficial. For example, the
PFTs should worsen over time as the patient approaches
diagnosis and treatment, with a subsequent gradual improve-
ment after antibiotics are started. The slope of the line is not
affected positively or negatively by either the diagnosis or
treatment of Nocardia. Figs. 1 and 2 show each patient's mean
FEV1 and FVC values, respectively, during a treatment episode.
No overall change is noted and there are no outliers on
individual analysis noted of individual plots.
Our results are consistent with the concept that Nocardia is
primarily a colonizer, not a pathogen, of bronchiectatic cystic
fibrosis lungs. Prior studies have linked bronchiectasis of all
causes with Nocardia colonization [10]. In our larger data set,
Nocardia spp. was isolated from sputum samples in 18
additional patients with known bronchiectasis of other causes
in the absence of cystic fibrosis. Whether or not these patients
are directly comparable to the cystic fibrosis patients is
unknown. This is a subject for further study.
This study suffers from weaknesses inherent to small
retrospective analyses. Some data was unavailable upon chart
review such as uniform antimicrobial sensitivities and doc-
umentation of patient symptoms. The inclusion of patient
symptomatology in the analysis would have been preferable,
however, it was technically not feasible and admittedly
subjective. We acknowledge that PFTs can be altered by a
wide array of factors including environmental, mechanical, and
infectious processes. Thus, the impact of oral antibiotics may
potentially have been overshadowed by more potent influences
such as allergen avoidance, improved pulmonary toilet, or
treatment of pseudomonal infections. We feel that the duration
320 S.T. Thorn et al. / Journal of Cystic Fibrosis 8 (2009) 316–320of analysis (1 year per episode) helps to minimize the effects of
these short term confounders as well as minimize the effect of
the natural progression of cystic fibrosis.
The study design amplified data from a small cohort to allow
adequately powered analysis. This method has promise for
application to other rare microorganisms found in cystic fibrosis
such as fungal infections and atypical mycobacteria. Clarifying
the role of these microorganisms would greatly add to our
knowledge of cystic fibrosis and help clinicians make evidence-
based antibiotic decisions in these patients.
5. Conclusions
Cystic fibrosis is a disease in which many different
microorganisms can be implicated in the progression of disease
over the lifetime of a single patient. It is often a challenge for
clinicians to determine the significance of positive sputum
cultures. Nocardia is one bacterium whose role in cystic fibrosis
remains unclear. Our study suggests that oral antibiotic therapy
directed at Nocardia in the sputum of cystic fibrosis patients has
no significant impact on the course of the underlying disease
process. A larger randomized trial would be needed to verify
this finding. These data support the ethical inclusion of a
placebo control group in any future research. In addition the
study model was successful in providing a strong analysis based
on a small total population. This model may potentially be
applied to many other infectious complications in which data isvery limited by the rarity of the microorganism and/or disease
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